HEPATOCELLULAR CARCINOMA Manal Abdel Hamid Associate Prof. Of medical oncology.
Correction: Precision Oncology for Hepatocellular Cancer ... · 1. Subbiah V, Pal SK. Precision...
2
326 | CANCER DISCOVERY FEBRUARY 2020 AACRJournals.org CORRECTION Correction: Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition In the original version of this article (1), “FGFR4” was incorrectly spelled as “FGF4” in the title, and “FGFR4” and “FGF19” were incorrectly spelled as “FGF4” and “FGFR19” in the Summary and the section titled “Acquired Resistance Paradigm in FGFR4, and Next Steps.” The latest online HTML and PDF versions of the article have been corrected. The authors and publisher regret the error. REFERENCE 1. Subbiah V, Pal SK. Precision oncology for hepatocellular cancer: slivering the liver by FGF19–FGFR4–KLB path- way inhibition. Cancer Discov 2019;9:1646–9. CORRECTION Published first February 5, 2020. Cancer Discov 2020;10:326 doi: 10.1158/2159-8290.CD-19-1447 ©2020 American Association for Cancer Research. Research. on July 27, 2021. © 2020 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from
Transcript of Correction: Precision Oncology for Hepatocellular Cancer ... · 1. Subbiah V, Pal SK. Precision...
326 | CANCER DISCOVERY FEBRUARY 2020 AACRJournals.org
CORRECTION
Correction: Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19–FGFR4–KLB Pathway Inhibition
In the original version of this article (1), “FGFR4” was incorrectly spelled as “FGF4” in the title, and “FGFR4” and “FGF19” were incorrectly spelled as “FGF4” and “FGFR19” in the Summary and the section titled “Acquired Resistance Paradigm in FGFR4, and Next Steps.” The latest online HTML and PDF versions of the article have been corrected. The authors and publisher regret the error.
REFERENCE1. Subbiah V, Pal SK. Precision oncology for hepatocellular cancer: slivering the liver by FGF19–FGFR4–KLB path-
way inhibition. Cancer Discov 2019;9:1646–9.
CORRECTION
Published first February 5, 2020.Cancer Discov 2020;10:326doi: 10.1158/2159-8290.CD-19-1447©2020 American Association for Cancer Research.
Research. on July 27, 2021. © 2020 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from
2020;10:326. Cancer Discov
KLB Pathway Inhibition−FGFR4−Slivering the Liver by FGF19 Correction: Precision Oncology for Hepatocellular Cancer:
Updated version
http://cancerdiscovery.aacrjournals.org/content/10/2/326
Access the most recent version of this article at:
Cited articles
http://cancerdiscovery.aacrjournals.org/content/10/2/326.full#ref-list-1
This article cites 1 articles, 1 of which you can access for free at:
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://cancerdiscovery.aacrjournals.org/content/10/2/326To request permission to re-use all or part of this article, use this link
Research. on July 27, 2021. © 2020 American Association for Cancercancerdiscovery.aacrjournals.org Downloaded from
